Journal Mobile Options
Table of Contents
Vol. 57, No. 4, 1999
Issue release date: November 1999
Oncology 1999;57:276–280

Clinical Implications of Lymph Node Micrometastases in Patients with Colorectal Cancers

A Case Control Study

Nakanishi Y. · Ochiai A. · Yamauchi Y. · Moriya Y. · Yoshimura K. · Hirohashi S.
aPathology and bCancer Information and Epidemiology Divisions, National Cancer Center Research Institute and cDepartment of Surgery, National Cancer Center Hospital, Tokyo, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


There is no unanimity about the prognostic significance of lymph node micrometastases from colorectal cancer. A case-control study of patients with recurrent and nonrecurrent colorectal cancer who were closely matched for the Dukes stage, extent of lymph node dissection, tumor size, tumor location, number of resected lymph nodes, age and gender was performed. The presence of micrometastases in a total of 1,633 lymph nodes from 44 patients (22 with and 22 without recurrence) were examined by immunohistochemistry using antibodies for cytokeratin (KL-1) and p53 (RSP53). Immunostaining with KL-1 revealed micrometastases in 15/22 patients [68%; 82/820 lymph nodes (10%)] and 15/22 patients [68%; 45/813 lymph nodes (6%)] in the recurrent and nonrecurrent groups, respectively. Immunohistochemical analysis, using RSP53, of 18 paired patients with p53-positive primary tumor revealed micrometastases in 4/9 patients [44%; (7/265 lymph nodes (2.6%)] and 4/9 patients [44%; 6/257 lymph nodes (2.3%)] with and without recurrence, respectively. Neither the micrometastatic frequencies of the patients nor the resected lymph nodes of the recurrent and nonrecurrent groups differed significantly. Micrometastases in regional lymph nodes are an interesting phenomenon, but do not influence patients’ prognoses if the involved lymph nodes are removed.

Copyright © 1999 S. Karger AG, Basel

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Chapuis PH, Dent OF, Fisher R, Newland RC, Pheils MT, Smyth E, Colquhoun K: A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg 1985;72:698–702.
  2. Fielding P, Phillips RKS, Fry JS, Hittinger R: Prediction of outcome after curative resection of large bowel cancer. Lancet 1986;ii:904–907.
  3. Greenson JK, Isenhart CE, Rice R, Mojzisik C, Houchens D, Martin EW: Identification of occult micrometastases in pericolic lymph nodes of Dukes’ B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Cancer 1994;73:563–569.
  4. Cutait R, Alves VAF, Lopes LC, Cutait DE, Borges JLA, Singer J, Silva JH, Goffi FS: Restaging of colorectal cancer based on the identification of lymph node micrometastases through immunoperoxidase staining of CEA and cytokeratins. Dis Colon Rectum 1991;34:917–920.
  5. Adell G, Boeryd B, Franlund B, Sjodahl R, Hakansson L: Occurrence and prognostic importance of micrometastases in regional lymph nodes in Dukes’ B colorectal carcinoma: An immunohistochemical study. Eur J Surg 1996;162:637–642.
  6. Broll R, Schauer V, Schimmelpenning H, Strik M, Woltmann A, Best R, Bruch HP, Duchrow M: Prognostic relevance of occult tumor cells in lymph nodes of colorectal carcinomas. Dis Colon Rectum 1997;40:1465–1471.
  7. Hayashi N, Ito I, Yanagisawa A, Kato Y, Nakamori S, Imaoka S, Watanabe H, Ogawa M, Nakamura Y: Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 1995;345:1257–1259.
  8. Liefers GJ, Jansen AMC, Van de Velde CJH, Hermans J, Krieken JHJM, Cornelisse CJ, Tollenaar RAEM: Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998;339:223–228.
  9. Japanese Society for Cancer of the Colon and Rectum: Japanese Classification of Colorectal Carcinoma, ed 1 (English). Tokyo, Kanehara, 1997.
  10. Nakanishi Y, Noguchi M, Matsuno Y, Saikawa M, Mukai K, Shimosato Y, Hirohashi S: P53 expression in multicentric squamous cell carcinoma and surrounding squamous epithelium of the upper aerodigestive tract. Cancer 1995;75:1657–1662.

    External Resources

  11. Sasaki M, Watanabe H, Jass JR, Ajioka Y, Kobayashi M, Hatakeyama K: Immunoperoxidase staining for cytokeratin 8 and 18 is very sensitive for detection of occult node metastasis of colorectal cancer: A comparison with genetic analysis of K-ras. Histopathology 1998;32:199–208.
  12. Moreno JG, Croce CM, Fischer R, Monne M, Vihko P, Mulholland SG, Gomella LG: Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 1992;52:6110–6112.
  13. Zimmermann DVV, Roijers JFM, Rombouts AB, Weger RAD, Graaf PWD, Tilanus MGJ, Tweel JG: Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. Am J Pathol 1996;149:759–764.
  14. Yamamoto N, Kato Y, Yanagisawa A, Ohta H, Takahashi T, Kitagawa T: Predictive value of genetic diagnosis for cancer micrometastasis. Cancer 1997;80:1393–1398.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50